The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment
- PMID: 25586212
- DOI: 10.1016/j.jpsychires.2014.12.018
The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment
Abstract
We aimed to characterize a large international cohort of outpatients with MDD within a practical trial design, in order to identify clinically useful predictors of outcomes with three common antidepressant medications in acute-phase treatment of major depressive disorder (MDD). The international Study to Predict Optimized Treatment in Depression has presently enrolled 1008 treatment-seeking outpatients (18-65 years old) at 17 sites (five countries). At pre-treatment, we characterized participants by symptoms, clinical history, functional status and comorbidity. Participants were randomized to receive escitalopram, sertraline or venlafaxine-extended release and managed by their physician following usual treatment practices. Symptoms, function, quality of life, and side-effect outcomes were assessed 8 weeks later. The relationship of anxiety to response and remission was assessed by comorbid Axis I diagnosis, presence/absence of anxiety symptoms, and dimensionally by anxiety symptom severity. The sample had moderate-to-severe symptoms, but substantial comorbidity and functional impairment. Of completers at week 8, 62.2% responded and 45.4% reached remission on the 17-item Hamilton Rating Scale for Depression; 53.3% and 37.6%, respectively on the 16-item Quick Inventory of Depressive Symptoms. Functional improvements were seen across all domains. Most participants had side effects that occurred with a frequency of 25% or less and were reported as being in the "none" to minimal/mild range for intensity and burden. Outcomes did not differ across medication groups. More severe anxiety symptoms at pre-treatment were associated with lower remission rates across all medications, independent of depressive severity, diagnostic comorbidity or side effects. Across medications, we found consistent and similar improvements in symptoms and function, and a dimensional prognostic effect of comorbid anxiety symptoms. These equivalent outcomes across treatments lay the foundation for identifying potential neurobiological and genetic predictors of treatment outcome in this sample.
Keywords: Escitalopram; International practical trial; Major depressive disorder; Response and remission; Sertraline; Venlafaxine-XR.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.Am J Psychiatry. 2015 Aug 1;172(8):743-50. doi: 10.1176/appi.ajp.2015.14020181. Epub 2015 Mar 27. Am J Psychiatry. 2015. PMID: 25815419 Clinical Trial.
-
Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression.Transl Psychiatry. 2016 May 3;6(5):e799. doi: 10.1038/tp.2016.61. Transl Psychiatry. 2016. PMID: 27138798 Free PMC article. Clinical Trial.
-
Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.J Clin Psychiatry. 2011 Oct;72(10):1322-32. doi: 10.4088/JCP.10m06724. J Clin Psychiatry. 2011. PMID: 22075098 Clinical Trial.
-
[Depressive symptoms during anorexia nervosa: State of the art and consequences for an appropriate use of antidepressants].Encephale. 2017 Feb;43(1):62-68. doi: 10.1016/j.encep.2016.02.017. Epub 2016 Jul 21. Encephale. 2017. PMID: 27452149 Review. French.
-
Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review.Psychiatry Res. 2016 Jun 30;240:421-430. doi: 10.1016/j.psychres.2016.04.034. Epub 2016 May 5. Psychiatry Res. 2016. PMID: 27155594 Review.
Cited by
-
Ketamine's mechanism of action with an emphasis on neuroimmune regulation: can the complement system complement ketamine's antidepressant effects?Mol Psychiatry. 2024 Apr 4. doi: 10.1038/s41380-024-02507-7. Online ahead of print. Mol Psychiatry. 2024. PMID: 38575806 Review.
-
Proteomic profiles of cytokines and chemokines in moderate to severe depression: Implications for comorbidities and biomarker discovery.Brain Behav Immun Health. 2024 Feb 7;36:100731. doi: 10.1016/j.bbih.2024.100731. eCollection 2024 Mar. Brain Behav Immun Health. 2024. PMID: 38435722 Free PMC article.
-
Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials.Br J Psychiatry. 2024 Mar;224(3):89-97. doi: 10.1192/bjp.2023.148. Br J Psychiatry. 2024. PMID: 38130122 Free PMC article.
-
Electronic health records and stratified psychiatry: bridge to precision treatment?Neuropsychopharmacology. 2024 Jan;49(1):285-290. doi: 10.1038/s41386-023-01724-y. Epub 2023 Sep 4. Neuropsychopharmacology. 2024. PMID: 37667021 Free PMC article. Review.
-
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA.Neuropsychiatr Dis Treat. 2023 Mar 31;19:693-707. doi: 10.2147/NDT.S391096. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 37025256 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical